Cargando…
Behavioral factors to modulate immunotherapy efficacy in cancer
Immune checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 therapies, are used to (re)activate the immune system to treat cancer. Despite promising results, a large group of patients does not respond to checkpoint inhibition. In the vulnerability-stress model of behavioral medicine, behaviora...
Autores principales: | Jongerius, C., Vermeulen, L., van Egmond, M., Evers, A. W. M., Buffart, L. M., Lenos, K. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9800824/ https://www.ncbi.nlm.nih.gov/pubmed/36591246 http://dx.doi.org/10.3389/fimmu.2022.1066359 |
Ejemplares similares
-
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
por: Duru, Gizem, et al.
Publicado: (2020) -
Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy
por: Shui, Lin, et al.
Publicado: (2020) -
Evaluation of immunotherapy efficacy in gynecologic cancer
por: Jiang, Genyi, et al.
Publicado: (2023) -
Toll-Like Receptor-4 Modulation for Cancer Immunotherapy
por: Awasthi, Shanjana
Publicado: (2014) -
The Efficacy of Cancer Immunotherapies Is Compromised by Helicobacter pylori Infection
por: Oster, Paul, et al.
Publicado: (2022)